FIGURE 2.

Time to relapse during double-blind treatment by week (double-blind intent-to-treat population). Log-rank test for treatment difference during week 24 to week 36 (P=.01). Relapse is defined as the worsening of restless legs syndrome symptoms (an increase of ≥6 points in the International Restless Legs Scale total score from double-blind baseline [week 24, randomization] to a score of ≥15 and a rating of “much worse” or “very much worse” on the investigator-rated Clinical Global Impression of Change on 2 consecutive visits ≥1 week apart) or withdrawal due to lack of efficacy during the double-blind phase.